Partner With Us NRI

Glenmark Pharmaceuticals Ltd share Price Today

Company details

6M Return 33.62%
1Y Return 70.11%
Mkt Cap.(Cr) 29,234.68
Volume 953,721
Div Yield 0.24%
OI Chg %
Volume 953,721

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Margin recovery hinges on key launches, cost control…
About The Stock

    Glenmark’s business is separated into three entities –

    • Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others
    • Glenmark Life Sciences for manufacturing and marketing APIs
    • Innovation new company (ICHNOS) to focus on discovery and development of novel, first‐in‐class treatments in therapeutic areas of immunology, oncology and pain encompassing both NBEs as well as NCEs

    In line revenues but EBITDA margins miss.

    • Revenues increased 9.2% YoY to ₹ 3463 crore
    • EBITDA was at ₹ 432 crore, down 10.5% YoY with margins at 17.9
    • Adjusted PAT was at ₹ 239 crore (down 40.4% YoY)

Click here for full recommendation

Research view on more stocks

Glenmark Pharmaceuticals announced Q1FY24 results:

  • Europe Business grew by 73.7% to Rs 5,732 million.
  • ROW Business grew by 30.4% to Rs 5,512 million.
  • North America Business grew by 22% to Rs 8,085 million.
  • India's Business grew by 2.8% to Rs 10,643 million.
  • EBITDA of Rs 6,312 million grew by 46.2% YoY, with margins of 18.6%.
  • Consolidated revenue was at Rs 34,016 million as against Rs 27,773 million recording an increase of 22.5% YoY.
  • Profit After Tax (PAT) for Q1FY24 was at Rs 1,731 million.

“We had yet another strong quarter both in terms of revenue and operating margins. The robust growth in sales was led by our branded markets in the RoW region. Our Europe business performed significantly well on the back of a strong generics portfolio and continued gains in market share, in our leading respiratory brands. Our North American business remained stable, and our India business continued to significantly outperform industry growth rates. We also had our GHG emission targets certified by the Science Based Targets initiative (SBTi) giving us an impetus to further pursue our ESG goals, while also benchmarking us at a global scale.” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

He further added, “Going forward our goal remains to sustain the momentum, as RYALTRIS continues to meaningfully contribute across all the covered markets. We also remain on track to achieve our objectives for FY24.”



Result PDF

View Other Company Results

Glenmark Pharmaceuticals Ltd shares SWOT Analysis

Strengths (5)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with Low Debt
  • Book Value per share Improving for last 2 years

Weakness (11)

  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years
  • Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years

Opportunity (2)

  • Stock with Low PE (PE < = 10)
  • High Volume, High Gain

Threats (2)

  • Promoter decreasing their shareholding
  • Increasing Trend in Non-Core Income

Resistance and support

R1 1,052.4
R2 1,068.8
R3 1,095.0


S1 1,009.8
S2 983.6
S3 967.2
Delivery and volume
ISHARES CORE MSCI EMERGING MARKETS ETF Block Purchase 2022-10-25 397.9 302621 BSE
ISHARES MSCI INDIA SMALL-CAP ETF Block Purchase 2022-10-25 397.9 39265 BSE
Name Category Shares


Investment recommendation
Margin recovery hinges on key launches, cost control…
Call Date
13 Feb 2023
Entry Price 410.00
Target Price 440.00
12-18 Month


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Glenmark Pharmaceuticals Ltd Stocks COMPARISON

Financials( in Cr) Glenmark Pharmaceuticals Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,036.00 1,486.70 1,486.45 4,122.40 1,076.00
% Change 0.82 -0.56 -0.18 0.23 -0.93
Mcap Cr 29,234.68 356,709.13 120,011.07 109,436.94 108,270.78
Revenue TTM Cr 12,990.11 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 377.40 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 470.64 35.64 28.16 79.13 28.08
1 Year Return 70.11 59.59 59.76 21.76 112.04
ROCE 14.28 16.79 14.76 19.30 16.25
ROE 6.91 16.46 10.66 14.89 14.05

Equity Capital: 9,473.93 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 36,628.54 -24,386.86
LAST 3M 102,786.44 -29,845.85
LAST 6M 169,824.52 52,410.32
LAST 12M 264,693.58 128,545.97
Board of Glenmark Pharmaceuticals recommends final dividend

May 25, 2024 l BSE Announcement

NSE Board Meetings Forthcomming

May 24, 2024 l NSE Board Meetings Forthcomming

Board Meeting for Today

May 24, 2024 l Board Meetings for Today

Date Action Type Ratio
Sep 18, 2023 Dividend 250
Sep 12, 2022 Dividend 250

Glenmark Pharmaceuticals Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Glenmark Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company manufacturing generic drugs and active pharmaceutical ingredients. It was founded in 1977 by Gracias Saldanha. The company’s headquarters are in Mumbai. For FY 2021-2022, Glenmark Pharmaceuticals Ltd.’s total revenue was Rs 12,471.58 crore, up 13.44% from Rs 10,994.15 crore in the previous financial year 2020-2021. On 8 August 2022, the company’s market capitalisation stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/glenmarkpharma/GP08" 10,483 crore. 

    The company is listed on the Bombay Stock Exchange with the code 532296 and on the National Stock Exchange with the code GLENMARK.  

    Glenmark Pharmaceuticals Ltd. is involved in developing and marketing branded and generic formulations. The company’s innovative drug discovery effort focuses on the areas of metabolic disorders (obesity, diabetes, etc.), inflammation (rheumatoid arthritis, asthma/COPD, etc.), and pain (inflammatory pain and neuropathic pain). It manufactures formulations across therapeutic areas of respiratory, diabetes, cardiac, dermatology, gynaecology, anti-infective, oncology, and CNS.  

    The company’s shareholding pattern on 30 June 2022 showed a promoter stake of 46.65%, foreign institutional investor stake of 24.23%, domestic institutional investor stake of 10.49%, and public stake of 18.62%. The Saldanha Family Trust is the leading promoter with a 45.45% share. During the quarter ended June 2022, mutual funds decreased holdings from 6.18% to 5.81%, with the number of mutual fund schemes reducing from 21 to 19.  

    Mr Glenn Saldanha is the company’s chairman and managing director. The top management comprises Mr D R Mehta, Mr Sridhar Gorthi, Mr Dipankar Bhattacharjee, Mr Rajesh V Desai, Mrs Cherylann Pinto, Mrs B E Saldanha, Mr Bernard Munos, Dr Brian W Tempest, Mr V S Mani, and Ms Saira Ramasastry. The auditors are Suresh Surana & Associates LLP and Walker, Chandiok & Co.LLP.  

    On 8 August 2022, Glenmark Pharmaceuticals Ltd.’s BSE share price was trending at Rs 372.45, while the NSE share price was trending at Rs 372.50. The 52-week high for Glenmark Pharmaceuticals Ltd.’s share price was Rs 597.90, and the 52-week low for the company’s share price was Rs 348.50.  

    The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

B/2 Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai, Maharashtra, 400026

Tel : 91-22-40189999
Email : complianceofficer:glenmarkpharma.com
Website : http://www.glenmarkpharma.com

Karvy Computershare Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 532296
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE935A01035

FAQ’s on Glenmark Pharmaceuticals Ltd Shares

You can buy Glenmark Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Pharmaceuticals Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2024 03:50 PM the closing price of Glenmark Pharmaceuticals Ltd was Rs.1,036.00.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 24, 2024 03:50 PM, the market cap of Glenmark Pharmaceuticals Ltd stood at Rs. 29,234.68.

The latest PE ratio of Glenmark Pharmaceuticals Ltd as of May 24, 2024 03:50 PM is 470.64

The latest PB ratio of Glenmark Pharmaceuticals Ltd as of May 24, 2024 03:50 PM is 0.32

The 52-week high of Glenmark Pharmaceuticals Ltd share price is Rs. 1,098.00 while the 52-week low is Rs. 587.00

According to analyst recommendations, Glenmark Pharmaceuticals Ltd Share has a "Buy" rating for the long term.

Download App

Download Our App

Play Store App Store
market app